KromaTiD Appoints Nathan Wood as Chief Executive Officer

 

Longmont, CO, August 12, 2021 – KromaTiD, Inc. announces that Nathan Wood, will be joining as its Chief Executive Officer.  Wood is a seasoned executive with thirty years of experience in the life science industry and is the former President and CEO of Swift Biosciences, Inc., a provider of research tools in the genomics and related health care industry.  Wood replaces Christopher Tompkins, who will assume the role of Chief Technology Officer.

“Nathan has well documented track record of success commercializing research tools.  He has been an executive and C-level contributor at a number of leading life science companies.  He is passionate about KromaTiD’s technology platform and the unique opportunities it has within the large and growing genomics market,” said Dr. Opgenorth, chairman of the company’s board of directors. “In short, he is a great business and culture fit for KromaTiD and we are confident he will lead the Company to the next stage and establish KromaTiD as yet another pioneering Colorado bioscience company in the genomics space.”

During his tenure with Swift Biosciences, Wood raised private funding totaling more than $15 million to develop and commercialize a proprietary set of NGS library preparation products that served research and clinical laboratory markets, substantially grew revenue, and merged Swift with IDT, a Danaher company.

Prior to Swift, Wood held leadership roles in sales, marketing, product development and management at leading companies in the genomics and life sciences industries, including Life Technologies Corporation and QIAGEN Inc. Nathan served on BIOCOM’s Renewables Advisory Board. He has also served on the Board of Directors of GeneArt, Blue Heron, SB Biofuels and the College of Science at Oregon State University where he earned his Bachelor’s degree.

About KromaTiD

KromaTiD, Inc. is a Colorado-based bioscience company dedicated to creating products for disease research, mutation detection and structural analysis of chromosomes. KromaTiD’s patented dGH™ chromosome imaging platform provides disease researchers with the ability to detect all types of DNA rearrangements including previously undetectable classes of mutations.  The company and its collaborators and customers expect that KromaTiD products will pave the way to enabling gene edited therapeutics, identifying new diagnostic targets, developing a better understanding of the genetic causes of a variety of important human diseases.  KromaTiD develops and markets dGH technology under license from Colorado State University.  For more information on products and services offered by KromaTiD, visit www.kromatid.com.